Prognostic significance of bcl-2, tumor-associated macrophages, and total neoplastic and inflammatory lymph node involvement in advanced stage classical hodgkin's lymphoma

Onkologie

Volumn 35, Issue 12, 2012, Pages 733-739

  Jakovic, Ljubomir R ^a   Mihaljevic, Biljana S ^a,b   Jovanovic, Maja D Perunicic ^a   Bogdanovic, Andrija D ^a,b   Andjelic, Bosko M ^a   Bumbasirevic, Vladimir Z ^b  

^a CLINICAL CENTER OF SERBIA   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Advanced Hodgkin's lymphoma; Prognostic parameters

Indexed keywords

BLEOMYCIN SULFATE; CD68 ANTIGEN; CISPLATIN; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; PROTEIN BCL 2; VINBLASTINE;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; EVENT FREE SURVIVAL; FEMALE; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; INFLAMMATORY CELL; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE; UNIVARIATE ANALYSIS;

ADOLESCENT; ADULT; AGED; COMORBIDITY; FEMALE; HODGKIN DISEASE; HUMANS; LYMPHANGITIS; LYMPHATIC METASTASIS; MACROPHAGES; MALE; MIDDLE AGED; PREVALENCE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RISK FACTORS; SERBIA; SURVIVAL ANALYSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84871050231     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/000343664     Document Type: Article

References (42)

1. Diehl V: Hematology. Are macrophages the bad guys in Hodgkin lymphoma? Nat Rev Clin Oncol 2010;7:301-2.
2. Brice P: Managing relapsed and refractory Hodgkin lymphoma. Br J Haematol 2008;141: 3-13.
3. Friedman DL, Constine LS: Late effects of treatment for Hodgkin lymphoma. J Natl Compr Canc Netw 2006;4:249-57.
4. Fuchs M, Diehl V, Re D: Current strategies and new approaches in the treatment of Hodgkin's lymphoma. Pathobiology 2006;73:126-40.
5. Zender T, Wiedenmann S, Wolf J: Prognostic factors in Hodgkin's lymphoma. Ann Oncol 2002;13: 67-74.
6. Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin's disease. N Engl J Med 1998;339: 1506-14.
7. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, Rosenberg SA, Coltman CA, Tubiana M: Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswold meeting. J Clin Oncol 1989;7:1630-6.
8. Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, Buus S, Keiding S, D'Amore F, Boesen AM, Berthelsen AK, Specht L: FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006;107:52-9.
9. Montalban C, Garcia JF, Abraira V, Gonzales-Camacho L, Morente MM, Bello JL, Conde E, Cruz MA, Garcia-Sanz R, Garcia-Larana J, Grande C, Llanos M, Martinez R, Flores E, Mendez M, Ponderos C, Rayon C, Sanchez-Godoy P, Zamora J, Piris MA: Influence of biologic markers on the outcome of Hodgkin's lymphoma: a study by the Spanish Hodgkin's Lymphoma Study Group. J Clin Oncol 2004;22: 1664-73.
10. Von Wasielewski R, Georgii A, Fischer R: Clinical impact of grading the nodular sclerosing Hodgkin's disease under modern therapy of the German Hodgkin Study Group. Leuk Lymphoma 1998;29: 0-3.
11. Garcia JF, Camacho FI, Morente M, Fraga M, Montalban C, Alvaro T, Bellas C, Castano A, Diez A, Flores T, Martin C, Martinez MA, Mazorra F, Menarguez J, Mestre MJ, Mollejo M, Saez AI, Sanchez L, Piris MA: Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints. Analysis using tissue microarrays. Blood 2003;101:681-9.
12. Kelley TW, Pohlman B, Elson P, Hsi ED: The ratio of FOXP3+ regulatory T cells to granzyme B+ cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. Am J Clin Pathol 2007; 128:958-65.
13. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD, Bast MA, Rosenwald A, Muller-Hermelink HK, Rimsza LM, Campo E, Delabie J, Braziel RM, Cook JR, Tubbs RR, Jaffe ES, Lens G, Connors JM, Staudt LM, Chan WC, Gascoyne RD: Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010;362:875-85.
14. Rautert R, Schinkothe T, Franklin J, Weinhrauch M, Boll B, Pogge E, Bredenfeld H, Engert A, Diehl V, Re D: Elevated pretreatment interleukin-10 serum level is an International Prognostic Score (IPS)-independent risk factor for early treatment failure in advanced stage Hodgkin lymphoma. Leuk Lymphoma 2008;49:2091-8.
15. Niens M, Visser L, Nolte IM, van der Steege G, Diepstra A, Cordano P, Jarret RF, Te Meerman GJ, Poppema S, van den Berg A: Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22. Br J Haematol 2008;140: 527-36.
16. Horning JS. Risk, cure and complications in advanced Hodgkin disease. Hematology Am Soc Hematol Educ Program 2007;197-203.
17. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW: WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, 4th ed. Lyon, International Agency for Research on Cancer, 2008.
18. Dukers DF, Meijer C, ten Berge RS, Vos W, Ossenkoppele GJ, Oudejans J. High numbers of active caspase 3-positive Reed-Sternberg cells in pretreatment biopsy specimens of patients with Hodgkin's disease predict favorable clinical outcome. Blood 2002;100:36-42.
19. Rassidakis GZ, Medeiros LJ, McDonell TJ, Viviani S, Bonfante V, Nadali G, Vassilakopoulos TP, Giardini R, Chilosi M, Kittas C, Gianni AM, Bonadonna G, Pizzolo G, Pangalis GA, Cabanillas F, Sarris AH: Bax expression in Hodgkin and Reed-Sternberg cells of Hodgkin's disease. Correlation with clinical outcome. Clin Cancer Res 2002;8: 488-93.
20. Von Wasielewski S, Franklin J, Fischer R, Hubner K, Hansmann ML, Diehl V, Georgii A, von Wasielewski R: Nodular sclerosing Hodgkin's disease: new grading predicts prognosis in intermediate and advanced stages. Blood 2003;101:4063-9.
21. Specht L: Tumour burden as the main indicator of prognosis in Hodgkin's disease. Eur J Cancer 1992; 28A:1982-5.
22. Axdorph U, Sjoberg J, Grimfors G, Landgren O, Porwit-MacDonald A, Bjorkholm M: Biological markers may add to prediction of outcome achieved by the international prognostic score in Hodgkin's disease. Ann Oncol 2000;11:1405-11.
23. Devilard E, Bertucci F, Trempat P, Bouabdallah R, Loroid B, Giaconia A, Brousset P, Granjeaud S, Nguyen C, Birnbaum D, Birg F, Houlgatte R, Xerri L: Gene expression profiling defines molecular subtypes of classical Hodgkin's disease. Oncogene 2002;21:3095-02.
24. Rassidakis GZ, Medeiros LJ, Vassilakopoulos TP, Viviani S, Bonfante V, Nadali G, Herling M, Angelopoulou MK, Giardiani R, Chilosi M, Kittas C, McDonnell TJ, Bonadonna G, Gianni AM, Pizzolo G, Pangalis GA, Cabanillas F, Sarris AH: Bcl-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens. Blood 2002;100:3935-41.
25. Canioni D, Deau-Fischer B, Taupin P, Ribrag V, Delarue R, Bosq J, Rubio MT, Roux D, Vasiliu V, Varet B, Brousse N, Hermine O: Prognostic significance of new immunohistochemical markers in refractory classical Hodgkin lymphoma: a study of 59 cases. PLoS One 2009;4:e6341.
26. Sup SJ, Alemany CA, Pohlman B, Elson P, Malhi S, Thakkar S, Steinle R, His ED: Expression of Bcl-2 in classical Hodgkin's lymphoma: an independent predictor of poor outcome. J Clin Oncol 2005;23:3773-9.
27. Sanchez-Espiridion B, Montalban C, Lopez A, Menarguez J, Sabín P, Ruiz-Marcellan C, Ruiz-Marcellan C, Lopez A, Ramos R, Rodriguez J, Canovas A, Camarero C, Canales M, Alves J, Arranz R, Acevedo A, Salar A, Serrano S, Bas A, Moraleda JM, Sanchez-Godoy P, Burgos F, Rayon C, Fresno MF, Larana JG, Garcia-Cosio M, Santonja C, Lopez JL, Llanos M, Mollejo M, Gonzales-Carrero J, Marin A, Forteza J, Garcia-Sanz R, Tomas JF, Morente MM, Piris MA, Garcia JF: A molecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma. Blood 2010;116:e12-e17.
28. Morente MM, Piris MA, Abraira V, Acevedo A, Aguilera B, Bellas C, Fraga M, Garcia-Del-Moral R, Gomez-Marcos F, Menargues J, Oliva H, Sanchez-Beato M, Montalban C: Adverse clinical outcome in Hodgkin's disease is associated with loss of retinoblastoma protein expression, high Ki67 proliferation index, and absence of Epstein-Barr virus-latent membrane protein 1 expression. Blood 1997;90:2429-36.
29. Spector N, Milito CB, Biasoli I, Luiz RR, Pulcheri W, Morais JC: The prognostic value of the expression of Bcl-2, p53 and LMP-1 in patients with Hodgkin's lymphoma. Leuk Lymphoma 2005;46:1301-6.
30. Qian BZ, Pollard JW: Macrophage diversity enhances tumor progression and metastasis. Cell 2010;141:39-51.
31. Farinha P, Masoudi H, Skinnider BF, Shumansky K, Spinelli JJ, Gill K, Klasa R, Voss N, Connors JM, Gascoyne RD: Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005;106:2169-74.
32. Burger JA, Ghia P, Rosenwald A, Caligaris-Capio F. The microenvoirement in mature B-cell malignancies: a target for new treatment strategies. Blood 2009;114:3367-75.
33. Tzankov A, Matter MS, Dimhofer S: Refined prognostic role of CD68 positive tumor macrophages in the context of the cellular micromilieu of classical Hodgkin lymphoma. Pathobiology 2010;77:301-8.
34. Jakovic LR, Mihaljevic BS, Perunicic Jovanovic MD, Bogdanovic AD, Andjelic BM, Bumbasirevic VZ: The prognostic relevance of tumor associated macrophages in advanced stage classical Hodgkin lymphoma. Leuk Lymphoma 2011;52:1913-9.
35. Yoon DH, Koh YW, Kang HJ, Kim S, Park CS, Lee SW, Suh C, Huh J: CD68 and CD163 as prognostic factors for Korean patients with Hodgkin lymphoma. Eur J Haematol 2012;88:292-305.
36. Kamper P, Bendix K, Hamilton-Dutoit S, Honore B, Nyengaard JR, d'Amore F: Tumorinfiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma. Haematologica 2011;96:269-76.
37. Sanchez-Aguilera A, Montalban C, de la Cueva P, Sanchez-Verde L, Morente MM, Garcia-Cosio M, Garcia-Larana J, Bellas C, Provencio M, Romagosa V, de Sevilla AF, Menarguez J, Sabin P, Mestre MJ, Mendez M, Fresno MF, Nicolas C, Piris MA, Garcia JF: Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood 2006; 108:662-8.
38. Azambuja D, Natkunam Y, Biasoli I, Lossos IS, Anderson MW, Morais JC, Spector N: Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma. Ann Oncol 2012;23:736-42.
39. Kaplan RN, Rafii S, Lyden D: Preparing the 'soil': the premetastatic niche. Cancer Res 2006;66: 11089-93.
40. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, Zhu Z, Hicklin D, Wu Y, Port JL, Altorki N, Port ER, Ruggero D, Schmelkov SV, Jensen KK, Rafii S, Lyden D: VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005;438:820-7.
41. Jones RJ, Gocke CD, Kasamon YL, Miller CB, Perkins B, Barber JP, Vala MS, Gerber JM, Gellert LL, Siedner M, Lemas MV, Brennan S, Ambinder RF, Matsui W: Circulating clonotypic B cells in classic Hodgkin lymphoma. Blood 2009; 113:5920-6.
42. Lorusso G, Rüegg C: The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem Cell Biol 2008;130: 1091-103.